Share Prices & Company Research

Stockbroking

Astrazeneca Plc

Current Price 15282.00p Bid 15242.00p Ask 15282.00p Change 0.12%
Last Updated: 21/02/2026 07:15. Prices delayed by at least 15 minutes.
Call 0113 243 6941 or search for your local office

Company Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

Financial Highlights Year Ended 31/12/2025

Revenue
£58,739.00m
Operating Profit/Loss
£13,743.00m
Dividend yield (%)
1.70
Total dividend for year
$n/a
Dividend cover
2.06
P/E Ratio
28.10
More Financials

Key Personnel

Mr Pascal Soriot
CEO and Executive director
Dr Aradhana Sarin
CFO & Executive Director
Dr Euan Ashley
Non-Executive Director
Mr Marcus Wallenberg
Non-Executive Director
Mr Michel Demare
Non-Executive Director
Mr Philip A J Broadley
Non-Executive Director
Mr Rene Haas
Non-Executive Director
Mr Tony Mok
Non-Executive Director
Mrs Nazneen Rahman
Non-Executive Director
Mrs Sheri McCoy
Non-Executive Director
Ms Anna Manz
Non-Executive Director
Ms Birgit Conix
Non-Executive Director
Ms Diana Layfield
Non-Executive Director
Ms Karen Knudsen
Non-Executive Director

Stock Details

EPIC
AZNL
ISIN
GB0009895292
Shares in Issue
1,264.16m
Market cap
£193,189.36m

Analyst Views (6)

Strong Buy
 
0%
Buy
 
83.33%
Hold
 
0%
Sell
 
16.67%
Strong Sell
 
0%
This information is provided by Web Financial Group (UK) Limited. It is subject to change without notice and doesn't reflect the views held by Redmayne Bentley and is not advice.

Price Summary

Mid Price
15,282.00p
Bid Price
15,242.00p
Ask Price
15,282.00p
Volume
294,039
Change Today
18.00p
% Change Today
0.12%
Open
15,419.00p
Previous Close
15,282.00p
Intraday High
15,424.00p
Intraday Low
15,226.00p
52 Week High
15,484.00p
52 Week Low
9,642.00p
52 week high and low figures quoted above are calculated from intraday price data.

Intra-Day Chart

More Charts

News

AstraZeneca's Calquence leukaemia treatment gets US FDA approval 20/02/2026 10:40:46 Shore Capital lowers AstraZeneca to 'hold' 13/02/2026 13:59:09 Annual sales, profits jump at AstraZeneca 10/02/2026 07:29:27 FDA rejects self-injectable version of AstraZeneca lupus drug 03/02/2026 07:34:29 Astrazeneca's Imfinzi receives EU recommendation from CHMP 02/02/2026 07:29:53 AstraZeneca strikes collaborative agreement with CSPC Pharmaceuticals 30/01/2026 07:03:09 AstraZeneca unveils $15bn China investment 29/01/2026 07:37:07 Citi starts AstraZeneca at 'buy', takes 'neutral' stance on GSK 27/01/2026 11:36:36 Director/PDMR Shareholding 22/12/2025 11:00:00 AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles 22/12/2025 08:52:23 Enhertu granted BTD for post-neoadjuvant early BC 22/12/2025 07:30:00 Update on LATIFY Phase III trial of ceralasertib 22/12/2025 07:00:08 Director/PDMR Shareholding 19/12/2025 11:00:00 AstraZeneca chalks up dual regulatory wins in cancer and immunology 16/12/2025 07:42:06 AstraZeneca secures US approval for Imfinzi in gastric cancer 26/11/2025 07:03:05 AstraZeneca to spend $2bn in US manufacturing push 24/11/2025 07:01:09 AstraZeneca receives FDA approval for expanded Koselugo usage 20/11/2025 07:12:16 Director dealings: 3i execs buy the dip, AstraZeneca CFO offloads shares 14/11/2025 13:53:40 AstraZeneca beats Q3 expectations, maintains FY outlook 06/11/2025 09:18:38 AstraZeneca's Koselugo receives EU approval 28/10/2025 07:03:59 Astrazeneca's Tezspire secures EU approval 22/10/2025 08:00:29 AstraZeneca lupus treatment gets EU approval 20/10/2025 07:03:07 Deutsche Bank downgrades AstraZeneca to 'sell' 16/10/2025 10:24:34 AstraZeneca to cut US drug prices in key White House deal 13/10/2025 07:01:55 AstraZeneca's Baxdrostat hits Phase III endpoint in resistant hypertension 07/10/2025 07:27:43

Income Statement

Year End Date
31 Dec 2025
31 Dec 2024
 
$ (M)
$ (M)
Continuing Operations
Revenue
58,739.00
54,073.00
Operating Profit/Loss
13,743.00
10,003.00
Net Interest
-1,334.00
-1,284.00
Pre-Tax Profit
12,402.00
8,691.00
Profit After Tax from continuing operations
10,233.00
7,041.00
Discontinued Operations
Profit After Tax
n/a
n/a
Profit/Loss for the Year
10,233.00
7,041.00
Attributable to:
Equity Holders of Parent Company
10,225.00
7,035.00
Minority Interests
8.00
6.00
Total Dividend Paid
$n/a
$n/a
Retained Profit/(Loss) for the Financial Year
n/a
n/a

Earnings per Share

Year End Date
31 Dec 2025
31 Dec 2024
Basic
660.00c
454.00c
Diluted
654.00c
450.00c
Adjusted
660.00c
454.00c
Dividend per Share
$n/a
$n/a

Assets

Year End Date
31 Dec 2025
31 Dec 2024
 
$ (M)
$ (M)
Non-Current Assets
Property, Plant & Equipment
14,703.00
11,647.00
Intangible Assets
59,088.00
58,202.00
Investment Properties
n/a
n/a
Investments
2,525.00
1,900.00
Other Financial Assets
n/a
n/a
Other Non-Current Assets
9,035.00
6,459.00
Current Assets
Inventories
6,557.00
5,288.00
Trade & Other Receivables
15,177.00
12,972.00
Cash at Bank & In Hand
5,711.00
5,488.00
Current Asset Investments
n/a
n/a
Other Current Assets
1,278.00
2,079.00
Other Assets
n/a
n/a
Total Assets
114,074.00
104,035.00

Liabilities

Year End Date
31 Dec 2025
31 Dec 2024
 
$ (M)
$ (M)
Current Liabilities
Borrowings
3,486.00
2,676.00
Other Current Liabilities
27,131.00
25,190.00
Total Current Liabilities
30,617.00
27,866.00
Non-Current Liabilities
Borrowings
26,136.00
27,619.00
Provisions
4,418.00
4,226.00
Other Non-Current Liabilities
4,184.00
3,453.00
Total Non-Current Liabilities
34,738.00
35,298.00
Other Liabilities
n/a
n/a
Total Liabilities
65,355.00
63,164.00

Net Assets

Year End Date
31 Dec 2025
31 Dec 2024
 
$ (M)
$ (M)
Net Assets
48,719.00
40,871.00

Capital & Reserves

Year End Date
31 Dec 2025
31 Dec 2024
 
$ (M)
$ (M)
Share Capital
388.00
388.00
Share Premium Account
35,266.00
35,226.00
Other Reserves
2,041.00
2,012.00
Retained Earnings
10,972.00
3,160.00
Shareholders Funds
48,667.00
40,786.00
Minority Interests/Other Equity
52.00
85.00
Total Equity
48,719.00
40,871.00

Dividend History

Type
Ex-Dividend Date
Payment Date
Payment
2nd Interim
19 Feb 2026
23 Mar 2026
217.00¢
1st Interim
07 Aug 2025
08 Sep 2025
103.00¢
2nd Interim
20 Feb 2025
24 Mar 2025
210.00¢
1st Interim
08 Aug 2024
09 Sep 2024
100.00¢
2nd Interim
22 Feb 2024
25 Mar 2024
197.00¢
1st Interim
10 Aug 2023
11 Sep 2023
93.00¢
2nd Interim
23 Feb 2023
27 Mar 2023
197.00¢
1st Interim
11 Aug 2022
12 Sep 2022
93.00¢
2nd Interim
24 Feb 2022
28 Mar 2022
197.00¢
1st Interim
12 Aug 2021
13 Sep 2021
90.00¢
2nd Interim
25 Feb 2021
29 Mar 2021
190.00¢
1st Interim
13 Aug 2020
14 Sep 2020
90.00¢
2nd Interim
27 Feb 2020
30 Mar 2020
190.00¢
1st Interim
08 Aug 2019
09 Sep 2019
90.00¢
2nd Interim
28 Feb 2019
27 Mar 2019
190.00¢
1st Interim
09 Aug 2018
10 Sep 2018
90.00¢
2nd Interim
15 Feb 2018
19 Mar 2018
190.00¢
1st Interim
10 Aug 2017
11 Sep 2017
90.00¢
2nd Interim
16 Feb 2017
20 Mar 2017
190.00¢
1st Interim
11 Aug 2016
12 Sep 2016
90.00¢
2nd Interim
17 Feb 2016
21 Mar 2016
190.00¢
1st Interim
13 Aug 2015
14 Sep 2015
90.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Final
03 Feb 2010
15 Mar 2010
171.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢
Interim
05 Aug 2009
14 Sep 2009
59.00¢

Dividend Metrics

Year End Date
31 Dec 2025
31 Dec 2024
Dividend growth
3.23%
6.90%
Dividend yield
1.70%
2.20%
Dividend cover
2.06
1.46


Cboe Global Markets® is a registered trade mark of Cboe Global Markets, Inc., a company incorporated in the United States of America with registered address at 400 South LaSalle Street, Chicago, IL 60605, USA. Cboe shall own any and all rights including without limitation Intellectual Property rights and any and all goodwill arising directly or indirectly out of the Recipient’s use of the “Cboe Global Markets®”, “Cboe®” and “Bats®”” trademarks. Neither Cboe nor its licensors accept any liability for any errors or omissions in the Cboe Europe Indices or underlying data. No further distribution of Cboe Europe data is permitted without Cboe’s express written consent.

The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.